2026版：已完成临床试验年报

CLINICAL

WhitePaper

2026EDITION

AnnualCompleted

ClinicalTrialsReport

Strongheadwindsandwindsofchange

DrewMuscara

TrialtroveAnalyst,Citeline

AlexNoll

TrialtroveAnalyst,Citeline

May2026

AnnualCompletedClinicalTrialsReport

Contents

Introduction03

ToplineTrialLandscapeMetrics

04

LeadingTrialSponsors

11

Top3TherapeuticAreas

15

CurrentEventsinClinicalTrialsandRelatedImpacts

32

KeyTakeaways

34

References

35

AbouttheAuthors

36

Appendix

37

2May2026Copyright©⃞2026PharmaIntelligenceUKLimited,aCitelinecompany(Unauthorizedphotocopyingprohibited)

AnnualCompletedClinicalTrialsReport

Introduction

Trialtroverecorded4,364industry-sponsored

clinicalstudiesfromPhaseIthroughPhase

III/IVthateitherreachedcompletedstatusorattainedprimaryendpointsduring2025.Thisisan11%decreasefromthepreviousyear,whichreported4,903completedtrials.Anadditional1,002trialswerenotedasterminatedin2025,

whichisa13%decreasefrom2024(1,153)

.1

Afterthelasttwoyearsofconsecutivegainsseenforcompletedstudiesacrossevery

therapeuticarea(TA),thisyear’sresults

landedmoreflat-footed,recordingminimal

advancementandevenmildtomoderate

regressionformostTAs.However,therewas

asignificantincreaseinthenumberoftrials

whichmeettheirprimaryendpointsin2025

andanincreaseinthenumberofpositive,

pivotaltrials,making2025ayearofqualityoverquantity.Theaveragesuccessrateincreased

forsponsorsthatcompletedatleast25positivetrialsthisyearandfordiseasesassociatedwithatleast25positivetrials.Additionally,alltop10sponsorsintheautoimmune/inflammation(A/I)therapeuticareahadahighersuccessratein

A/Itrials.

Incomparisonwiththesponsorrepresentation,thetop20pharmacompaniesagainachievedahighdegreeofperformanceinseveralofthetoplinetrialmetricsandtopTAcoverage.The

resultsdisplayedsimilarityinthemeasurementstothosenotedlastyear,withconsideration

tocompletedtrialsandpositiveresults,but

haveaccountedforloweroverallnumbersfrom

thoseseenin2024.Allotherpharma(AOP)

alsodisplayedadecreaseintotalactivitybut

didamounttonearlytwofoldmoretrialsthan

thetop20pharmaanddefinitivelyestablished

presenceinthepipelinestatusdrugsforpositive,pivotalresults.Throughouttheanalysis,new

trendsbecomeapparent,notonlyforhowtheindustryfaredin2025,butalsofornewfocus

diseases,novelpharmaceuticalsinthepipeline,keycompanycontributions,wins,andmore.

Theseresultsarepulledannuallytoreflectthelandscapeofthepharmaceuticalindustry.

Thisassessmentreflectsasnapshotofthe

industry,andresultschangeasthedatabase

iscontinuallyupdated.Astheseresultsare

extractedatthesamepointeveryyear,we

arealsoreliantuponthetrialdetailstobe

publiclydisclosedforourtrialresultspriorto

theanalysis.Theseresultsarealsosubjectto

reportingbiasordelaysastrialcompletions

aredeterminedfromavarietyofpublicsources(trialregistries,pressreleases,etc.).In2025,thegovernmentshutdownreportedlydelayedthe

processingandpostingofclinicaltrialrecords

toClinicalT.

2

Thesedelayscouldhave

affectedourdataforthefourthquarterof2025.

3May2026Copyright©⃞2026PharmaIntelligenceUKLimited,aCitelinecompany(Unauthorizedphotocopyingprohibited)

AnnualCompletedClinicalTrialsReport

ToplineTrialLandscapeMetrics

Thecompletedtrialresultcountsof2025for

therepresentedTAsareevaluatedwithinTable1andreflecttheassignedTArankvalueand

correspondingtrialtotals.Thereislimited

surprisethatthroughthisyear’sevaluation,

oncologyremainsinthefirst-placeranking

forcompletedtrialactivity.TheoncologyTA

volumeshavecontinuedtomaintainahigh

numberofcompletedstudies,despitemarginaldifferencesorevensetbacksobservedin

thealternateTAs.Tocompare,theNo.2TA(A/I)posted702fewertrialsthanoncology.

Oncologydisplayedmildregressioninthetotalnumberoftrials(1,421vs.1,466).Alternatively,metabolic/endocrinology(met/endo)displayedacontinuationingrowthasitiscapturedinthetopthreeTAsforthe2025results.

ThroughouttheanalysisoftherespectiveTAs,

minimalshufflingisfoundintherankingofeachTA.Comparingtheresultstothatof2024,there

isadecisivedeclineintheoverallcountoftrialsinalmosteveryTA.However,forthefirsttime

inthehistoryofourcompletedtrialevaluation,met/endohassteppedintothetopthree.

Met/endo’sthird-rankplacementcanlargely

beattributedtothevastuptickincompleted

obesityandtype2diabetes(T2D)trials.This

valuationalsocomesoffthebackoftheCNS

TAfacinganoteworthydropincompletedtrialvalue,withsome123fewercompletedstudiesreportedcomparedtotheyearbefore.AnotherTAthatfacedconsiderableoppositioninthe

numberofrecordedtrialcompletionswas

infectiousdiseases(ID).Throughthecourseoflastyear,IDreported182fewertrialsthanin

2024.ThenumberofIDtrialcompletionshadbeenonasteep,upwardtrajectoryfollowingtheCOVID-19pandemic;however,inthemostrecentyear’sresults,adisparityemerges

wheretheresultsviolentlytoppledtonearpre-pandemicvolumes.

Table1:Trialcountsandrankingsforcompletedtrials,byyear

Therapeuticarea

Ranking

Trialcount*

2025

2024

2023

2022

2025

2024

2023

2022

Oncology

1

1

1

1

1,421

1,466

1,197

1,096

Autoimmune/Inflammation

2

2

2

2

719

828

758

669

Metabolic/Endocrinology

3

4

4

5

706

698

649

570

CNS

4

3

3

4

688

811

678

619

Cardiovascular

5

6

6

6

329

377

358

293

InfectiousDiseases

6

5

5

3

490

672

648

643

Vaccines

7

7

7

7

208

288

286

255

Ophthalmology

8

8

8

8

111

146

136

121

Genitourinary

9

9

9

9

44

70

62

58

*TrialsmayspanmultipletherapeuticareasSource:Trialtrove,February2026

4May2026Copyright©⃞2026PharmaIntelligenceUKLimited,aCitelinecompany(Unauthorizedphotocopyingprohibited)

AnnualCompletedClinicalTrialsReport

Unlikethepastfouryearsofsuccessivegrowth,therelativeannualchangesinTA-specifictrialactivityhadaresoundingdecline.OutofeachTA,onlymet/endoexhibitedadvancementas

thepercentagechangecalculatedtoameager1.1%abovelastyear’shigh.Throughoutthe

remainingeightTAs,theaveragepercentagedropaccumulatedto20%lessthan2024’s

results.Predominantly,themostsignificantdeclineswererelegatedto-55%inID,-37%forgenitourinary(GU),-28%invaccines,and

-24%forophthalmology.AcrosstheotherTAs,

lesssubstantialdropswereobservedforCNS

(-15%),cardiovascularandA/I(-13%each),

andoncology(-3%).Thepercentagedecline

reflectsthetangibleimpactdrivenbyarangeoffactors,includingregulatorychanges,economicconditions,andgeopoliticalevents.These

include,butarenotlimitedto,shiftsinFDAdisruptions,governmentshutdowns,fundingcuts,andgrantlosses.

Figure1:Relativeannualchangesincompletedtrialcounts,bytherapeuticarea

140%

120%

Percentannualchange

100%

80%

60%

40%

20%

0%

-20%

-40%

-60%

-80%

20252024202320222021

uOncologyAutoimmune/InflammationuCNSUMetabolic/EndocrinologyuCardiovascular

InfectiousDiseasesVaccinesOphthalmologyGenitourinary

Source:Trialtrove,February2026

5May2026Copyright©⃞2026PharmaIntelligenceUKLimited,aCitelinecompany(Unauthorizedphotocopyingprohibited)

AnnualCompletedClinicalTrialsReport

Distributionof2025completedtrialsbytherapeuticareaandphase

Therewerenegligiblechangesinthedistributionoftrialsbetweenphases.Consistentwithprior

years’analysis,earlyphasetrials(I,I/II,II)

constitutethemajorityofcompletedtrials.Ashasbeenthecasesince2022,oncologyhasthehighestproportionofPhaseI–IItrials(85%),

andvaccineshavethelowestproportionofPhaseI–IItrials(62%).

Whilethedistributionoftrialsbetweenphases

didnotchangesignificantly,thenumberof

completedtrialsdecreasedbyanaverageof

23.3%forearlyphasetrialsand14.5%forlate-

phasetrials;themostmarkeddifferencewasa40%decreaseinearlystageGUtrials(47to28).Onlythemet/endoandoncologytherapeutic

areassawgrowth,bothinlate-stagetrials,withmet/endorisingby15%(148to170)

andoncologyrisingby13%(186to211).This

increaseinlate-stagemet/endoclinicaltrial

activitycanlargelybeattributedtotheincreaseinGLP-1trials.

Figure2:Distributionofindustry-sponsoredtrialscompletedin2025,bytherapyareaandphase

Oncology

Autoimmune/Inflammation

CNS

Metabolic/Endocrinology

InfectiousDiseases

Cardiovascular

Vaccines

Ophthalmology

Genitourinary

26

219511

185

480

210

41831

28734

180

15150

31429

164

10160

33735

15

15280948

9

89

665

160

287

711

5447

122

2631382

8

2016

0100300500700900110013001500

II/IIIIII/IIIIIIIII/IV

Source:Trialtrove,February2026

6May2026Copyright©⃞2026PharmaIntelligenceUKLimited,aCitelinecompany(Unauthorizedphotocopyingprohibited)

AnnualCompletedClinicalTrialsReport

Topreportedtrialdiseases

Althoughseveralofthekeydiseasesnotedin

2024returnedinthisyear’strialevaluations,

thetop10diseasesfortrialcompletionsin

2025(Table2)offeredrearrangementofthese

indications.Thetopreportedtrialdiseasesare

composedofbothprevalentandrarecancers,

high-impactingmetabolicdiseases,andaviralinfection.Inthecourseofayear,onlythree

indicationsmaintainedtheirpreviouslyrecordedranking,whichwerenon-smallcelllungcancer

(1),T2D(3),andcolorectalcancer(5).Despiteeachofthediseaseshavingsimilarranking

totheyearbefore,onlynon-smallcelllung

cancer(NSCLC)andcolorectalcancer(CRC)increasedtheirrepresentationofcompleted

studies.NSCLCfollowslastyear’sresultsandagainreflectsdominanceinthetopspot.CRCalsocontinuestoholditsownasitonceagainremainsinthetopfive.

Jumpingsevenplacesintosecond,obesity

displacedbreastcancer.In2025,obesity

bolstereditstrialvolumesasitcompleted59

morestudiesthanin2024.Theriseincompletedstudiesforthisdiseaseandtheconsistency

ofT2D’strialnumberslargelyinfluencedwhy

met/endoTAiscapturedinthetopthreeTAs.

Uponfurtherreviewofthediseasearea’s

experimentaldrugmechanismsofaction,the

largestproportionineachofthesedisease

areaswererepresentedbycompletedtrials

testingexperimentalglucagon-likepeptide-1

receptoragonist(GLP-1RA)drugs(73%in

obesityand59%inT2D).Thestudiesdisplayedarenewedinterestinexpandingmodalitiesfor

GLP-1RAdrugsfromtheupheavalofcompletedobesitytrials.

Advanceswerealsodisplayedforalternateindications,whichnotonlyincreasedtrial

volumebutalsolaidnewgroundinranking.

Indicationsthatexperiencedpositiverank

movementandgainsincompletedtrialsbeyondobesitywerenon-Hodgkin’slymphoma(6)

andhead/neckcancer(7),bothfallwithintherarediseasecategory.Otherconditionsthat

improvedinrankbutdeclinedintrialvolumeswerepancreaticcancer(8),whichlistedthree

fewertrialscompleted,andovariancancer(10)whichreportedsixfewertrialsandreappearedinthetop10.Again,bothindicationsare

designatedasrare,reflectingarisingcommitmentinrarediseaseresearch.

7May2026Copyright©⃞2026PharmaIntelligenceUKLimited,aCitelinecompany(Unauthorizedphotocopyingprohibited)

AnnualCompletedClinicalTrialsReport

Twoindicationsdeclinedinrank:breastcancerandnovelcoronavirus(COVID-19).Each

diseasedisplayednormalizationinthenumberofcompletedtrials,albeitforvaryingreasons.

Breastcancertrialtotalsappeartohave

regressedtopreviousvaluesobserved(in2022)forthediseaseasitloweredcompletedcountsby55.Eventhoughbreastcancershowedlowercompletedtrials,severalstudiesachieved

primaryendpointsandembodiedadispositionofqualityoverquantity.Separately,COVID-19continuesadownwardtrendmarkingcontinuityinourassessmentsnotedinour2024Annual

CompletedClinicalTrialsReport

1

forfurther

stabilizationinthetrialtotalsforthisdisease.

ThepersistenceoflowerCOVID-19trialssincethepeakrecordedin2021(354),inconjunctionwithstrictervaccinepolicyannouncedbythe

USFoodandDrugAdministration(FDA),trackstowardtrendsmovingevenlowerin2026.

3

Amongthecompaniesthatcontributedto

completedtrialdiseaseareas,wefindprominentresultsnotedfromAstraZeneca(AZ)andDaiichiSankyo,withproductslikeEnhertu,forHER2-

positivebreastcancer.AdditionallyweighinginwasEliLillyforthepositiveresultsoutlinedintheirPhaseIIITRIUMPHtrialofretatrutide

.4

Table2:Top10diseasesfortrialscompletedin2025andcomparisontopriorthreeyears

Disease

2025

2024

2023

2022

Non-smallcelllungcancer

254(1)

242(1)

202(3)

160(4)

Obesity

184(2)

125(9)

88(12)

54(30)

Type2diabetes

179(3)

205(3)

205(2)

182(2)

Breastcancer

176(4)

231(2)

155(5)

174(3)

Colorectalcancer

151(5)

149(5)

101(7)

102(7)

Non-Hodgkin'slymphoma*

147(6)

134(7)

119(6)

115(6)

Head/Neckcancer*

130(7)

125(8)

88(11)

85(12)

Pancreaticcancer*

121(8)

124(10)

71(24)

54(31)

Novelcoronavirus(2019-nCoV,COVID-19)

117(9)

196(4)

255(1)

304(1)

Ovariancancer*

110(10)

116(14)

85(15)

82(13)

*RarediseaseSource:Trialtrove,February2026

8May2026Copyright©⃞2026PharmaIntelligenceUKLimited,aCitelinecompany(Unauthorizedphotocopyingprohibited)

AnnualCompletedClinicalTrialsReport

Trialsuccessrates

Completedtrialsareassignedanoutcome

evaluation(positive,negative,unknown,or

indeterminate)whetherthosestudiespublicly

disclosedsafety,efficacy,orbiomarker/surrogate

efficacyoutcomes.Thesuccessratesofeach

diseasewereassessedandcategorizedbased

uponthosethatexhibitedthegreatestproportionofpositiveoutcomesandwererankedbasedonthesuccessoftotalcompletedtrialsin2025

(Table3).

Table3:Diseaseswith≥25completedtrialsattainingprimaryendpoint

Disease

I

I/II

II

II/III

III

III/IV

Total

%ofall

trials

Rank#

Influenzavaccines

2

2

10

0

14

0

28

75.7%

1

Respiratoryvaccines

10

8

12

8

28

0

66

64.7%

2

Novelcoronavirus(2019-nCoV,COVID-19)

15

7

19

8

24

0

73

62.4%

3

Parkinson'sdisease

15

2

8

0

3

0

28

57.1%

4

Non-Hodgkin'slymphoma*

17

9

35

0

9

0

70

47.6%

5

Ulcerativecolitis

15

0

8

0

6

0

29

47.5%

6

Psoriasis

13

1

4

0

19

0

37

45.1%

7

NAFLD

13

0

12

0

2

0

27

42.9%

8

Obesity

21

3

30

2

21

0

77

41.8%

9

Esophagealcancer*

13

11

13

3

4

0

44

41.5%

10

Rheumatoidarthritis

15

1

4

0

4

1

25

41.0%

11

Atopicdermatitis

14

0

9

0

13

0

36

40.9%

12

Acutemyelogenousleukemia

6

11

5

0

3

0

25

40.3%

13

Neuroendocrinecancer*

4

14

10

0

4

0

32

40.0%

14

Gastriccancer

14

9

14

2

4

0

43

39.8%

15

Breastcancer

20

6

24

2

18

0

70

39.8%

16

Nociceptivepain

10

0

5

1

11

0

27

36.5%

17

Non-smallcelllungcancer

25

18

31

0

16

0

90

35.4%

18

Bladdercancer

11

4

7

1

7

0

30

35.3%

19

Colorectalcancer

20

15

12

0

6

0

53

35.1%

20

Type2diabetes

15

1

17

0

29

0

62

34.6%

21

Prostatecancer

10

4

12

1

5

0

32

34.4%

22

Dyslipidemia

6

0

7

0

21

0

34

34.3%

23

Pancreaticcancer*

11

15

10

0

2

0

38

31.4%

24

Renaldisease

9

3

11

1

4

0

28

30.8%

25

Ovariancancer*

7

10

9

0

5

0

31

28.2%

26

Head/neckcancer*

16

5

10

1

4

0

36

27.7%

27

*Raredisease

Rank#basedonpercentageoftrialsattainingprimaryoutcomeperdiseaseSource:Trialtrove,February2026

9May2026Copyright©⃞2026PharmaIntelligenceUKLimited,aCitelinecompany(Unauthorizedphotocopyingprohibited)

AnnualCompletedClinicalTrialsReport

Thenumberofdiseaseswhichmeetprimary

endpointsinatleast25trialsessentiallydid

notchangefrom2024to2025(25vs.27),buttheaveragesuccessrateamongdiseases

withatleast25positivetrialsrosefrom31%to42%.Additionally,theaveragesuccessratefordiseasesrankedinthetop10forpositivetrialswas53%,asubstantialincreasefrom2024’s

averageof36%.Thisprovidesfurtherevidenceofatrendseenacrossmultipletherapeutic

areasandwithmultiplesponsors,wherefewertrialswerecompleted,butagreaterproportionofcompletedtrialshadpositiveresults.

Alltop10diseasesbytotalcompletedtrials

countsinTable2achievedatleast25successfultrialsin2025.Novelcoronavirus,non-Hodgkin’slymphoma,andobesityallrankamongthe

top10,bothbycompletedtrialcountsaswellasbysuccessrate.Aswithlastyear,therearemoreoncologicalindicationsonthisgraph

thananyothertherapeuticareaandnoGU,ophthalmology,orIDindicationssurpassedthe25-trialthresholdtoqualifythemforthisanalysis.Theindustry’scommitmenttorarediseaseresearchisapparentthisyearas

well,withfiverare,oncologicalindicationscompleting25ormorepositivetrials.

Influenzavaccines,ulcerativecolitis,NAFLD(non-alcoholicfattyliverdisease),and

Parkinson’sdiseasedidnotmeetprimary

endpointsinatleast25trialsin2024,butin

2025wereinthetop10diseaseswhenranked

bysuccessrate.Respiratoryvaccines,novel

coronavirusvaccines,non-Hodgkin’slymphomaandpsoriasisremainedinthetop10by

successratethisyear,althoughnon-Hodgkin’slymphomarosefromninthtofifthplacein2025andcompleted26moretrials.Obesityfellfromthirdtoninthplace,butcompletedsevenmoretrials,largelyduetocompletingmorethantwiceasmanylate-stagetrialsthisyear(10vs.23)

andincreasingresearchinGLP-1medications.

Parkinson’sdiseaseresearchhassimilarly

expandedinrecentyears,withmorethanhalfofdrugsindevelopmentaimingtoslowdiseaseprogressionandseveralalphasynucleinPET

tracersbeingdevelopedtoenableustomoreaccuratelytrackthatprogressioninliving

patients.

5

,

6

Breastcancer,bladdercancer,renaldisease,

anddyslipidemiacompletedfewersuccessful

trialsthisyear,sotheyfelloutofthetop10

whenrankedbysuccessrate.Breastcancer

wentfromsixthto16thplaceandcompleted10fewerpositivetrialsin2025vs.2024,althoughitssuccessrateroseslightlyfrom35%to40%.

Dyslipidemiafellfromeighthto23rdplacewithanalmostidenticalsuccessrate(33%to34%),bladdercancerfellfromfifthto19thplacewithanunchangedsuccessrate,andrenaldiseasefellfromseventhto25th(34%to31%).

10May2026Copyright©⃞2026PharmaIntelligenceUKLimited,aCitelinecompany(Unauthorizedphotocopyingprohibited)

AnnualCompletedClinicalTrialsReport

LeadingTrialSponsors

Redirectingtoassesssponsorshipforthe

completedtrials,eachofthesponsoring

company’strialresultswereaggregatedand

quantifiedfor2025.Inthisassessment,the

companyresultsarereflectiveoftop20industrypharma,asdeterminedbysalesdatainthe

annualInVivoOutlook2026results,aswell

asadditionalAOP,excludinggenerics-only

companies

.7

Inthetopfivesponsorsevaluation,forcompletedtrials,thesehavehistorically

beencomprisedoftop20industrysponsors

andcontinuetoreflectthisgrouping(Table4).

Forthesecondyearinarow,Merck&Co.is

listedasthetoprankingsponsorforcompletedtrialresults.Merck&Co.nearlyreplicatedtheirresultsin2025astherewasonlyadifference

of18trials(210vs.228).Moreover,the

companyconsistentlyupheldnotorietyinthe

oncologyspaceasitsaw123trialscompleted

forthelistedTA,amerefivecompletedtrial

differencesfromthatrecordedlastyear(data

notshown).Returningtothesecondranking,AZdemonstratedsignificantresolveasitwasnot

onlylistedinthetopfiveleadingtrialsponsorsbutalsowasamongthetopfivesponsors

recordedineachofthetopthreeTAs.Roche

distinguisheditselfthroughthecompleted

resultsasitrosetothirdfromfifthandaddedthreecompletedtrialsoverthepreviouscount.

Competitionwasobservedforthefourth-placerankasBristolMyersSquibb(BMS)andEliLillyreflectedmirrored,completedstudyvolumesin2025.Followingupthetopfivesponsors,Pfizerdroppedthreerankvaluesasthecompany

markedlywenttofifthfromsecond.

Agranularanalysisofthetotalnumberof

completedtrialsforthetop20industrysponsorsdisplayedacountof1,683trialsthisyear,adropof9%overthe1,853individualtrialsrecorded

in2024.Additionally,AOPsponsorstabulated

atotalof2,872completedstudiesin2025,a

nearly12%declinefromthe3,263completed

studiesrecordedin2024.Astheresultsare

furthercompared,thesharesoftop20and

AOPsponsornumberslastyearpresenteda

percentageevaluationof38%(top20)vs.69%(AOP),whereinthisyeartheseobservations

continueastop20obtainedaslightincrease

inshare,raisinganadditionalpercentagepointandAOPdroppedthreepercentagepoints(39%vs.66%).

Table4:Topfivesponsors*completingtrialsin2021–2025

Sponsor

2025(rank)

2024(rank)

2023(rank)

2022(rank)

2021(rank)

Merck&Co

210(1)

228(1)

152(3)

116(4)

140(3)

AstraZeneca

174(2)

192(3)

170(2)

159(2)

175(2)

Roche

155(3)

152(5)

118(6)

116(4)

115(7)

BristolMyersSquibb

133(4)

184(4)

147(4)

142(3)

177(1)

EliLilly

133(4)

111(6)

110(7)

90(7)

121(6)

Pfizer

118(5)

218(2)

174(1)

165(1)

134(4)

*TrialcountincludescosponsoredtrialsSource:Trialtrove,February2026

11May2026Copyright©⃞2026PharmaIntelligenceUKLimited,aCitelinecompany(Unauthorizedphotocopyingprohibited)

AnnualCompletedClinicalTrialsReport

Successofindustrysponsorswasmeasured

bytheiroverallcountsofpositivetrialsthat

attainedprimaryendpointsandwasdispersedbytrialphaseinTable5.Thenumberof

sponsorsdemonstrating25ormorepositive

trialsreturnedto11afteronly10sponsorsmetthesecriteriain2024.Afterlastyear’sfindings,SanofiandAbbViehaveeachreturnedinthe

analysisnotingmorethan25studieswith

positiveresults,whileGSKwasnotincludedinthedatasetaftercompletingonly22trialswithpositiveresults.Moreover,thelistofcompaniesmatchesthoseoutlinedinour2023report,

sponsor-for-sponsor,althoughrearrangementwasfound.

Divingfurtherintothepositiveresults,AZ

hasachievedthetopsuccessfulpositionin

thisanalysisforthepastthreeyears.AZhas

consistentlyreportedsuccessfulpositivetrial

resultsinexcessof60(63in2025,68in2024,

and64in2023),whichhasledtoitstoppositioninthetable.Additionally,risingtotheoccasion,Rochefoundsuccessin13moretrialsthanin

ourpreviouscoveragetonowreport58studieswhereprimaryendpointsweremet.Merck&

Co.alsomadestridestomaintainitsstandingasitdisplayedamodest52trials.Lookingat

thetotalsbetweencompanyresultsfrom2025and2024,thesevaluesshowthatsponsorsareimprovingonstudieswhichmeettheirprimaryendpointsasthisyear439trialswerenotedforthesumofcompanies,vs.lastyearwhichlisted419trials.

Table5:Companiesattainingprimaryendpointsin≥25trials,byphase(2025)

Sponsor

I

I/II

II

II/III

III

III/IV

Total

AstraZeneca

4

3

24

0

32

0

63

Roche

10

8

21

0

19

0

58

Merck&Co

4

2

30

1

15

0

52

EliLilly

6

3

15

0

17

0

41

JiangsuHengrui

Pharmaceuticals

15

0

15

0

8

0

38

Sanofi

7

0

14

0

16

0

37

Novartis

8

3

7

0

17

0

35

BristolMyersSquibb

7

5

14

1

6

0

33

Johnson&Johnson

6

2

7

0

14

0

29

Pfizer

9

2

10

0

6

0

27

AbbVie

4

3

4

0

14

1

26

Source:Trialtrove,February2026

12May2026Copyright©⃞2026PharmaIntelligenceUKLimited,aCitelinecompany(Unauthorizedphotocopyingprohibited)

AnnualCompletedClinicalTrialsReport

Analternateevaluationofsponsorscompletingaminimumof40trialswasalsocompleted

andthesuccessofcorrespondingtrialswasdeterminedbytheindividualphaseand

totaltrialpercentages(Table6).Manyof

thecompaniescapturedwithinthissection

returnedfromprecedinganalysesandthe

top20sponsoringcompaniesaccounted

forthemainproportionofresults(17outof

20).TheremainingAOPsponsorswereSino

Biopharmaceutical,JiangsuHengruiPharma,

andIncyteCorporation.Eachofthecompanies,displayedinthetopfivepubliclyreported

attainingprimaryendpointsin40%ormore

oftheirtrials.SinoBiopharmaceuticalagain

ledwiththemostsignificantpercentageof

trialsobtainingprimaryendpoints(44.4%);

itstrialsprimarilyengagedthecountryof

China.JiangsuHengruiPharma,anotherAOP

companyacquiringahighdegreeoftrial

success(40.9%),alsoexclusivelyconducted

trialsinChina.Numeroustop20sponsors

averagedhigherpercentagesoftrialsobtainingprimaryendpointsin2025,whichconsisted

ofAmgen,Sanofi,Novartis,Roche,AbbVie,

EliLilly,Takeda,andPfizer.BothAmgen

andSanofielevatedtheirprimaryendpoint

percentagesastheymovedintothetopfive

positions.Amgenrecordednearlydoubletheper